PET imaging of early response to the tyrosine kinase inhibitor ZD4190.

ABSTRACT:

Purpose

We evaluated noninvasive positron emission tomography (PET) imaging for monitoring tumor response to the VEGFR-2 tyrosine kinase (TK) inhibitor ZD4190 during cancer therapy.

Experimental design

Orthotopic MDA-MB-435 tumor-bearing mice were treated with ZD4190 (100 mg/kg orally per day for three consecutive days). Tumor growth was monitored by caliper measurement. During the therapeutic period, longitudinal PET scans were acquired using (18)F-FDG, (18)F-FLT and (18)F-FPPRGD2 as imaging tracers to evaluate tumor glucose metabolism, tumor cell proliferation, and angiogenesis, respectively. Imaging metrics were validated by immunohistochemical analysis of Ki67, GLUT-1, F4/80, CD31, murine integrin β3, and human integrin αvβ3.

Results

Three consecutive daily oral a

SUBMITTER: Yang M 

PROVIDER: S-EPMC3184245 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature